All In Biotech

Drug Trial Radar · NCT04386616

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia

Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

Jun 2, 2020

Primary completion

Jan 8, 2021

Study completion Feb 12, 2021

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
May 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.

Conditions

  • COVID-19 Pneumonia

Interventions

  • MSTT1041ADrug

    Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.

  • MSTT1041A-matched PlaceboDrug

    Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.

  • UTTR1147ADrug

    Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.

  • UTTR1147A-matched PlaceboDrug

    Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28Time frame: From Baseline up to 28 days

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Arkansas For Medical Sciences

    Little Rock, Arkansas

  • eStudySite - Chula Vista - PPDS

    Chula Vista, California

  • eStudySite

    La Mesa, California

  • Torrance Memorial Medical Center

    Torrance, California

  • Denver Health Medical Center

    Denver, Colorado

  • Bay Pines VA Medical Center - NAVREF

    Bay Pines, Florida

  • WellStar Research Institute

    Marietta, Georgia

  • DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS

    Alexandria, Louisiana

  • MedPharmics

    Metairie, Louisiana

  • Southeast Louisiana Veterans Health Care System - NAVREF

    New Orleans, Louisiana

  • Henry Ford Health System

    Detroit, Michigan

  • St. Joseph'S Regional Medical Center

    Paterson, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Albany Medical Center

    Albany, New York

  • Staten Island University Hospital; Department of Pharmacy

    Staten Island, New York

  • Lincoln Medical Mental Health Center

    The Bronx, New York

  • Mercy St. Vincent Medical Center

    Toledo, Ohio

  • Providence Portland Medical Center; Investigational Drug Services/Regional Research

    Portland, Oregon

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Parkland Health & Hospital System

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

  • MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility

    Tacoma, Washington

  • Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Santa Casa de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital E Maternidade Celso Pierro PUCCAMP

    Campinas, São Paulo, Brazil

  • Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Hospital Alemao Oswaldo Cruz

    São Paulo, São Paulo, Brazil

  • Instituto do Coração - HCFMUSP

    São Paulo, São Paulo, Brazil

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    México, Mexico

  • Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases

    México, Mexico

  • Hospital General de Tijuana

    Tijuana, Mexico

  • Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca

    Guadalajara, Jalisco, Mexico

  • Hospital Universitario Dr. Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, Mexico

  • Hospital del Mar

    Barcelona, Spain

  • Hospital General Universitario de Guadalajara

    Guadalajara, Spain

  • Complejo Asistencial Universitario de Salamanca - H. Clinico

    Salamanca, Spain

  • Hospital Clinico Universitario Valladolid

    Valladolid, Spain

  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.